Vertex Pharmaceuticals spent decades turning a deep understanding of cystic fibrosis biology into one of biotechnology's strongest franchises. Reshma Kewalramani is now asking the company to repeat that process across several diseases at once. In the first quarter of 2026, revenue rose 8 per cent to $2.99 billion, and more than a quarter of the increase came from CASGEVY, the gene-edited therapy, and JOURNAVX, a non-opioid pain medicine.
The next diversification test is kidney disease. Vertex completed a rolling US application for povetacicept in IgA nephropathy, seeking accelerated approval, while advancing the medicine in other immune-mediated conditions including primary membranous nephropathy and generalised myasthenia gravis. Management describes nephrology as a fourth major franchise, alongside cystic fibrosis, acute pain and sickle-cell disease.
For Kewalramani, a physician-scientist who became chief executive in 2020, the opportunity is substantial. Kidney diseases affect large populations and can lead to dialysis, transplantation and high health-system costs. The standard of proof is equally high. Vertex must show that povetacicept delivers durable clinical benefit, can be used safely across broad populations and earns access in a field attracting intense competition.
Diversification has moved from promise to revenue
Vertex's cystic fibrosis medicines remain the financial engine. They generate the cash that funds research, acquisitions, launches and manufacturing. The franchise is protected by strong clinical benefit and broad patient reach, but no company can rely indefinitely on one therapeutic area. Kewalramani's strategy has been to invest the cash flow in diseases where Vertex believes it can change treatment rather than pursue diversification for its own sake.
CASGEVY and JOURNAVX are important because they demonstrate two different capabilities. CASGEVY requires a complex treatment pathway involving specialised centres, cell collection, editing and conditioning. JOURNAVX is a more conventional medicine aimed at a very broad need, but it enters a market shaped by low-cost generics and entrenched prescribing habits. Success in both would show that Vertex can commercialise beyond its familiar rare-disease model.
The fact that the two products contributed more than 25 per cent of first-quarter growth is encouraging. It does not yet establish mature franchises. Launches often move unevenly as centres are activated, reimbursement is negotiated and physicians gain experience. Kewalramani must keep investors focused on patient access and durable use rather than early quarterly fluctuations.
Kidney disease adds another commercial model. Nephrologists manage chronic patients over long periods, and treatment choice depends on evidence that a medicine preserves organ function, not merely changes a laboratory marker. Vertex's reputation for rigorous development can help, but it has to be earned again in this field.
Povetacicept is a platform-sized bet
Povetacicept is designed to inhibit signals involved in the survival and activity of antibody-producing cells. That mechanism makes it relevant to diseases in which harmful antibodies contribute to tissue damage. In IgA nephropathy, abnormal immune activity can progressively impair kidney function. A therapy that meaningfully alters the course of disease could reach a large global market.
Accelerated approval can bring a medicine to patients based on a surrogate endpoint reasonably likely to predict clinical benefit, while confirmatory evidence continues. The pathway can be valuable in serious disease, but it increases the importance of follow-up. Vertex must complete trials that demonstrate the effect on outcomes patients and health systems ultimately care about.
Kewalramani should treat the application not as a finish line but as the beginning of a long evidence programme. Physicians will compare povetacicept with established supportive care and a growing set of targeted medicines. Safety, dosing convenience, durability and compatibility with other treatments will shape its place in practice.
The expansion into membranous nephropathy and myasthenia gravis tests whether the mechanism can support a broader immunology franchise. Shared biology may create development and commercial efficiencies, but each condition has its own endpoints, specialists and competitive landscape. Platform language is useful only when it produces repeatable clinical advantage.
The R&D bill demands selectivity
Vertex reported roughly $1.5 billion in combined research, development and related operating expenses in the first quarter. That level reflects a company funding multiple late-stage programmes and new launches from a strong base. It also creates a clear expectation: spending must translate into assets with a credible route to substantial patient and economic value.
Kewalramani has expanded the portfolio through internal discovery and transactions. This approach can reduce dependence on a single research engine, but it also raises integration and prioritisation challenges. Programmes acquired at attractive scientific stages still need Vertex's development resources, and not all can move at the same speed.
Selectivity is part of innovation. Vertex should stop or partner projects that no longer meet its standards, even when the underlying science remains interesting. The company's cystic fibrosis success was built on sustained focus, not on pursuing every opportunity. Repeating that success across four franchises requires strong leaders with authority to allocate resources and end work when evidence changes.
Investors will watch whether operating expenses rise ahead of revenue for a prolonged period. Near-term investment is justified when launches and late-stage programmes are de-risking. It becomes harder to defend if timelines slip or commercial uptake remains modest. Kewalramani's communication should connect major spending clearly to development and launch milestones.
Commercial success starts with diagnosis and access
Kidney disease is often diagnosed late, and specialist access varies widely. A new medicine cannot reach eligible patients if testing and referral pathways are weak. Vertex may need to support disease education and diagnostic capacity while maintaining appropriate boundaries between commercial activity and clinical decision-making.
Payer scrutiny will be intense because chronic treatment can create large cumulative costs. Evidence that povetacicept delays dialysis or transplantation would be clinically meaningful and economically powerful, but such outcomes take time to measure. Interim endpoints must be credible, and pricing should reflect both uncertainty and value.
The global opportunity is particularly important in Asia, where kidney disease creates a large and growing burden. Genetic, environmental and health-system differences can affect diagnosis and treatment patterns. Vertex will need local evidence, regulatory plans and reimbursement strategies rather than relying entirely on US launch assumptions.
Manufacturing also matters. Biological medicines require reliable production and quality control. A broad chronic-disease launch can demand more supply than a rare-disease programme. Kewalramani must ensure capacity grows with approval scenarios without building expensive facilities far ahead of confirmed demand.
The cystic fibrosis standard is demanding
Vertex's cystic fibrosis franchise set an unusually high internal benchmark. The company linked disease biology to targeted medicines, expanded treatment to more patients through successive combinations and built a durable commercial position. Patients experienced substantial benefit, which supported access and pricing. The business generated cash that transformed the company.
Not every new franchise will follow the same trajectory. Pain medicine has a broader population and different pricing. Gene editing involves a complex one-time treatment. Kidney disease sits between those models: large enough to support major revenue, specialised enough that clinical differentiation can matter. Kewalramani must set targets appropriate to each field while preserving the same standard of evidence.
There is also a cultural risk in past success. A company with a dominant franchise can assume its development judgement will transfer automatically. New specialists, commercial capabilities and external partnerships are needed. Kewalramani's own medical background can help bridge science and strategy, but organisational humility is essential.
The goal is not to recreate cystic fibrosis mechanically. It is to recreate the process that made the franchise valuable: choose diseases with tractable biology, build decisive evidence, work closely with specialist care and maintain investment over years. Povetacicept will show whether that process can travel.
Competition will clarify the product's value
IgA nephropathy has become an active area for drug development. Therapies address different parts of the disease, including immune pathways, kidney protection and the production of pathogenic antibodies. This creates opportunities for combinations as well as direct competition.
Vertex needs evidence that helps physicians decide which patients should receive povetacicept, at what stage and alongside which treatments. Broad average results may be less useful than clear understanding of response, durability and safety across patient groups. Biomarkers could improve selection, but they must be practical in routine care.
A competitive field can accelerate diagnosis and awareness, expanding the treated market. It also gives payers alternatives and can limit pricing power. The strongest defence is clinically meaningful differentiation that remains visible outside tightly controlled trials. Real-world evidence will matter after launch.
Kewalramani should welcome this scrutiny. A fourth franchise will be more durable if it is built on comparative value rather than the temporary advantage of being early. The company has the resources to fund long follow-up and post-approval study; it should use them.
The next phase is proof at scale
Vertex's first-quarter growth shows that diversification is beginning to contribute. CASGEVY and JOURNAVX are moving from approval stories to commercial operations. Povetacicept could add a larger chronic-disease opportunity and create a base for further immune-mediated programmes.
The scorecard for Kewalramani should include more than regulatory dates. Patient starts, treatment-centre capacity, payer access, persistence and evidence generation will show whether the franchises are becoming durable. Research productivity and operating expense should be assessed alongside the quality of these launches.
Vertex has a rare strategic advantage: a highly profitable core business and the ability to invest through setbacks. That advantage can be wasted through overextension or converted into a multi-franchise company with decades of growth. The difference will come from choosing where the science is strongest and executing every practical step between a molecule and a patient.
Reshma Kewalramani has opened the door to Vertex's next identity. Kidney medicine now has to meet the standard that made the company exceptional: evidence strong enough to change care, access broad enough to reach patients and economics durable enough to fund the next discovery. Povetacicept is not merely another launch. It is a test of whether Vertex's method can compound.
